J&J stock reclaims its 50-day SMA, but falling earnings estimates, a premium valuation and MedTech weakness raise questions about its near-term outlook.

UK approves J&J's oral psoriasis pill

Diversify Advisory Services LLC cut its holdings in Johnson and Johnson (NYSE: JNJ) by 2.8% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 92,125 shares of the company's stock after selling 2,609 shares during the period. Diversify Advisory Services LLC's holdings in Johnson

Cohen Investment Advisors LLC trimmed its position in shares of Johnson and Johnson (NYSE: JNJ) by 8.0% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 22,749 shares of the company's stock after selling 1,981 shares during the

Defensive consumer and healthcare stocks are drawing fresh money. As large-caps generally fall, Procter & Gamble‘s (NYSE:PG | PG Price Prediction) quarterly beat is catching the interest of today's buyers.

Johnson and Johnson just posted a quarter where one business charged ahead while another quietly stalled, and which side wins out will determine whether the stock earns its premium valuation over rivals like Merck and AbbVie.

A 3.3% Social Security bump leaves most retirees short, but five blue-chip dividend payers across four sectors have quietly built the kind of growing income stream that picks up where the government leaves off.

IRVINE, Calif.--(BUSINESS WIRE)--Johnson & Johnson reports first real-world VARIPULSE Pro Platform data and 12-Month OMNYPULSE Platform outcomes for atrial fibrillation treatment.